Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CL2020 in ARDS associated with SARS-CoV-2 infection
jRCT2043210005Completed
- Sponsor
- Life Science Institute
- Start
- Apr 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of CL2020 in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by Life Science Institute. Primary endpoints: Safety (STEP 1) and Mortality at 4 weeks (STEP 2). Started Apr 2021; status: completed.
02
Drugs
CL2020
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2043210005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043210005.